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Newborn bloodspot screening has been operating successfully in Australia for almost 
50  years. Recently, the development of new technologies and treatments has led to 
calls for the addition of new conditions to the screening programs. Internationally, it is 
recognized by governments that national policies for newborn screening should support 
transparent and evidence-based decision making, and promote consistency between 
states within a country. Australia is lagging behind the international community, and
currently has no national policies or decision-making processes, agreed by government, 
to support its newborn screening programs. In contrast, New Zealand (NZ), the United 
Kingdom (UK), and the United States of America (US) have robust and transparent
processes to assess conditions for screening, which have been developed by, and have 
pathways to, government. This review provides detail on the current policy environment 
for newborn screening in Australia, highlighting that there are a number of risks to the 
programs resulting from the lack of a decision-making process. It also describes the 
processes used to assess conditions for newborn screening in the US, UK, and NZ. 
These examples highlight the benefits of developing a national decision-making process, 
including ensuring that screening is evidence based and effective. These examples also 
provide models that might be considered for Australia, as well as other countries cur-
rently seeking to introduce or expand newborn bloodspot screening.
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introduction
Newborn bloodspot screening is an important public health program that has been operating glob-
ally since the 1960s. It aims to screen all newborns to detect a range of potentially life-threatening 
conditions before symptoms present. Typically, all of the conditions for which screening is offered 
benefit from early intervention, with treatment often preventing physical and mental disability, and 
death (1). Due to differences in government policy, structure, and priorities, the number of condi-
tions screened varies dramatically around the world, with some countries providing no newborn 
bloodspot screening, and others screening for more than 40 conditions (2).
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There are many conditions, in addition to those currently 
screened, which could be included in newborn screening programs. 
This is due to ongoing identification of new tests and treatments, 
which make screening for more conditions technically possible. 
For example, prior to 2005, severe combined immunodeficiency 
(SCID) could not be included in newborn screening as there was 
no method of testing for the condition using a dried bloodspot. 
With the development of a successful method for bloodspot 
screening for SCID, a number of pilot studies were conducted. 
Some countries, including the US, now recommend the condition 
for inclusion in newborn screening programs (3). The develop-
ment of new tests, such as the one for SCID, has led to calls to 
expand current programs, and it is likely that such calls will be 
ongoing. This is particularly relevant as genomic technologies, 
which can screen for a vast number of conditions, are becoming 
more readily available in the clinical setting (4–6).
When considering new conditions for screening, there is 
a need to ensure that it continues to benefit the individual, 
community, and health system as well as minimize harm (7). 
Therefore, the decision to add or remove conditions to newborn 
screening programs should only be made after a careful assess-
ment of the evidence about benefits and risks. In order to facilitate 
such an assessment, a methodological decision-making process 
is required. A number of governments around the world have 
developed such frameworks to ensure the appropriateness and 
effectiveness of screening.
The criteria used to assess conditions for screening around the 
world are based on the Wilson and Jungner principles of early 
disease detection, included in Box 1 (8). These principles were 
adopted by the World Health Organization (WHO) and, while 
considered the gold standard, have been criticized for being ill-
defined and too theoretical (9). In most instances, governments 
have adapted the WHO criteria to suit the local environment 
and include more detail specific to newborn screening (10). The 
adaptations have resulted in varying decision-making criteria and 
subsequent discrepancies in the number of conditions screened 
between countries. For example, the United States (US) recom-
mends screening for 29 conditions while the United Kingdom 
(UK) screens for nine, with four of those conditions only becom-
ing part of the UK’s screening program in early 2015. In addition 
to differences in the screening criteria, there are differences in the 
extent that these processes have been tested over time. For exam-
ple, the decision-making process in the UK is well established and 
has been in place since 2009, whereas the most recent US process 
was only formalized in April 2013. While there are many inter-
national examples of decision-making processes for newborn 
screening, this review focuses on those from New Zealand (NZ), 
US, and UK as they are the most relevant to Australia.
The Australian Setting
Newborn screening has been operating successfully in Australia 
for almost 50 years across the six federated states and two ter-
ritories. More than 99% of all babies are screened for around 25 
genetic and metabolic conditions (11, 12). In Australia, newborn 
screening programs are funded by state and territory govern-
ments and operate independently of each other. This funding 
model means each state and territory makes its own decisions 
regarding screening, including which conditions to screen. In 
the past half century, the programs have undergone significant 
change, growing from an initiative, which screened for a single 
condition, phenylketonuria, to the programs we see today. Despite 
these changes, there has been no specific policy or process, agreed 
by governments, to guide decisions regarding which conditions 
should be screened.
In Australia, changes to newborn screening programs have 
been made in an ad hoc manner, usually reactively and often in 
response to new technologies. Historically, one state or territory 
has implemented a new technology, or begun screening for an 
additional condition, and others have followed suit. The key 
example of this was the introduction in the late 1990s of tandem 
mass spectrometry in screening laboratories, which was followed 
by an expansion in the conditions screened. This technology ena-
bles simultaneous testing for a vast number of conditions. New 
South Wales piloted the technology in 1998, followed by South 
Australia in 1999. Screening with tandem mass spectrometry 
became universal in Australia in 2005, with other states adopting 
the technology as they could secure funding for the equipment.
The introduction of tandem mass spectrometry resulted in 
the addition of around 20 new conditions to screening protocols. 
The decision to implement new technology was supported by 
the Royal Australasian College of Physicians and the Human 
Genetics Society of Australasia. However, governments did 
not follow a transparent decision-making process to assess the 
evidence regarding benefits and harms of screening for individual 
conditions. Instead, decisions were made in response to the 
developing inequalities in the conditions screened between states, 
with technology as the initial driver.
The expanded screening programs, which emerged following 
the implementation of tandem mass spectrometry were, and 
remain, relatively stable and consistent. The key exception is the 
Victorian laboratory which does not screen for galactosemia. It 
can be argued, with considerable merit, that the high level of 
BOX 1 | wHO principles of early disease detection (8).
Condition
• The condition should be an important health problem.
• There should be a recognisable latent or early symptomatic stage.
• The natural history of the condition, including development from latent 
to declared disease should be adequately understood.
Test
• There should be a suitable test or examination.
• The test should be acceptable to the population.
Treatment
• There should be an accepted treatment for patients with recognised 
disease.
Screening Program
• There should be an agreed policy on whom to treat as patients.
• Facilities for diagnosis and treatment should be available.
• The cost of case-findings (including diagnosis and treatment of 
patients diagnosed) should be economically balanced in relation to 
possible expenditure on medical care as a whole.
• Case-findings should be a continuing process and not a ‘once and for 
all’ project.
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consistency is due to the dedication and professionalism of the 
newborn screening program leaders and the strong professional 
networks that exist. It can also be argued that an approach, which 
relies so strongly on internal drivers, is not sustainable to sup-
port ongoing decision making within and about programs. This 
is evidenced through a decade-long proposal to have congenital 
adrenal hyperplasia (CAH), a rare and potentially fatal condi-
tion, assessed for inclusion in newborn screening programs (4, 
13). Despite significant efforts from those within the programs 
to have CAH assessed, the issue has been referred back and forth 
among state, territory, and Commonwealth governments with-
out any decision being made (14, 15). This is largely due to the 
lack of an agreed decision-making process fit for this purpose, 
indicating that the current approach falls short of what is now 
required.
Since newborn screening was last expanded in the early 2000s, 
Australia’s commitment to population-based screening has 
evolved considerably. There is now recognition of the national 
structures, policies, and processes required to support effective 
and efficient population-based screening. Central to this has 
been the establishment of the Australian Screening Advisory 
Committee in 2001, now known as the Standing Committee 
on Screening (SCoS). This committee is tasked with providing 
guidance to the national cancer screening programs and consid-
ers emerging screening issues. SCoS comprises senior health 
officials, with expertise in screening, from the state, territory, and 
Commonwealth health departments.
Historically, SCoS and its former iterations have focused 
primarily on the national screening programs for breast, cervical, 
and bowel cancer. These programs are funded either solely by 
the Commonwealth Government or through partnership with 
state and territory governments. In addition to SCoS’s focus on 
cancer screening programs, it also considers emerging screening 
issues of national significance. It has developed national policies 
for newborn hearing screening, reviewed the evidence for lung 
cancer screening and released a position statement on prostate 
cancer screening (16). Despite this, SCoS has never been involved 
in providing policy guidance for newborn screening. However, 
this has recently changed. In the past year, SCoS has recognized 
the importance of national guidance for newborn screening and is 
now in the early stages of developing a national policy framework 
for newborn screening, which will include a decision-making 
framework (17).
In Australia, SCoS has played an important role in providing 
guidance on what constitutes a good screening program through 
the development of the Population-Based Screening Framework in 
2008 (Box 2) (7). The framework is based on the WHO Principles 
and has been endorsed by the Australian Health Ministers’ 
Advisory Council, with the aim of guiding decision makers when 
implementing screening programs (7). The development of this 
framework highlights that Australian governments recognize 
the importance of clear decision-making processes and policies 
for population-based screening programs. While it does provide 
some high level guidance, it lacks specific and relevant detail to 
enable an assessment of rare genetic conditions for newborn 
screening. For this reason, the framework is not sufficient to act 
as the sole decision-making guide for newborn screening.
BOX 2 | Australian population-based screening framework: screening 
program requirements (7).
The Screening Program must:
• respond to a recognised need.
• have a clear definition of the objectives of the programand the 
expected health benefits.
• have scientific evidence of screening program effectiveness.
• identify the target population which stands to benefit from screening.
• clearly define the screening pathway and interval.
• ensure availability of the organisation, infrastructure, facilities and 
workforce needed to deliver the screening program.
• have measures available that have been demonstrated to be cost 
effective to encourage high coverage.
• have adequate facilities available for having tests and interpreting 
them.
• have an organised quality control program across the screening 
pathway to minimise potential risks of screening.
• have a referral system for management of any abnormalities found and 
for providing information about normal screening tests.
• have adequate facilities for follow-up assessment, diagnosis, manage-
ment and treatment.
• have evidence based guidelines and policies for assessment, diagno-
sis and support for people with a positive test result.
• have adequate resources available to set up and maintaina database 
of health information collected for the program.
• integrate education, testing, clinical services and program 
management.
• have a database capable of providing a population register for people 
screened that can issue invitations for initial screening, recall indivi-
duals for repeat screening, follow those with identified abnormalities, 
correlate with morbidity and mortality results and monitor and evaluate 
the program and its impact.
• plan evaluation from the outset and ensure that program data are 
maintained so that evaluation and monitoring of the program can be 
performed regularly.
• be cost-effective.
• ensure informed choice, confidentiality and respect for autonomy.
• promote equity and access to screening for the entire target 
population.
• ensure the overall benefits of screening outweigh the harm.
In 2011, the Human Genetics Society of Australasia, in con-
junction with the Division of Paediatrics of the Royal Australasian 
College of Physicians, released its policy recommendations 
for newborn screening (1). These recommendations stressed 
that there is an “urgent need for the development of a national 
evidence-based process to evaluate proposals for changes to the 
conditions covered by newborn screening programs” (1). The 
policy includes a tool to assess the appropriateness of conditions 
for newborn screening in the Australian context, and a list of 
conditions recommended for screening. This is the sole example 
of national decision-making guidance for newborn screening in 
Australia. However, it has not been adopted by governments and, 
hence, does not translate into policy.
It is apparent that newborn screening in Australia is operating 
in an environment, which lacks a considered decision-making 
process for government, particularly in regards to assessing 
conditions for screening. This poses a risk to the programs as 
it could result in conditions not being thoroughly assessed in a 
consistent manner across Australia, prior to implementation – or 
exclusion. This may lead to unnecessary harms for parents and 
babies, including increased anxiety, as a result of false positive 
September 2015 | Volume 3 | Article 2144
Metternick-Jones et al. International newborn screening review
Frontiers in Public Health | www.frontiersin.org
results or indeterminate results of uncertain significance (18). 
The past ad  hoc and technology-driven approach is no longer 
appropriate, and is unable to produce the transparent and care-
fully balanced decisions that programs require. Changes to the 
programs should be informed by the result of a robust process 
that allow evidence about the benefits and harms of screening 
to be carefully considered. This will ensure that screening is 
informed by the best possible evidence, provides the greatest 
utility and is driven by what is best for the newborn (19). While 
professional networks have recognized this need, governments 
have been slower to respond, and thus decision making for the 
programs has stalled.
international experiences
Decisions to expand newborn screening programs have his-
torically been determined by “advances in technology, medical 
opinion, and pressure from interest groups, rather than through 
an evidence-based process” (20). In contrast, the international 
examples explored in this review show that having a cohesive 
process to manage the introduction of new conditions ensures 
an evidence-based approach, and promotes consistency and 
transparency across jurisdictions (19, 20).
New Zealand
In NZ, the National Screening Unit (NSU) is responsible for the 
“safety, effectiveness, and quality of organized screening pro-
grams,” including the Newborn Metabolic Screening Programme. 
The NSU is responsible for funding, contracting, auditing, and 
monitoring of services as well as policy development, guidelines, 
and consumer resources. It contracts one screening laboratory 
that is responsible for the testing and reporting of samples, which 
makes its structure notably different from Australia. The NSU 
also works closely with maternity services, the screening labora-
tory, and the metabolic clinical team to ensure screening is timely 
and of high quality.
Prior to the development of a decision-making framework 
to assess new conditions for newborn screening in 2011, NZ 
expanded its program to include a number of rare metabolic con-
ditions. This expansion came with the implementation of tandem 
mass spectrometry in 2006, after the equipment was gifted to the 
program by a charitable organization (21). The resulting expan-
sion was spurred by evidence indicating that metabolic disorders 
were being underdiagnosed in NZ (22).
In 2011, the NSU published the Newborn Metabolic Screening 
Programme Policy Framework, which outlined national poli-
cies, including the process for assessing conditions suitable for 
population-based newborn screening (23). The decision-making 
process involves the nomination of a condition, either by a health 
professional, an interested organization, a patient support group 
or a member of the public. If the NSU deems there is sufficient 
evidence to support further consideration, the nominated condi-
tion is assessed by the Programme Governance Team.
The Governance Team may request further information, 
such as an evidence review, cost benefit analysis, analysis against 
the screening criteria, and/or stakeholder consultation. The 
Programme Governance Team then provides advice to the NSU 
for or against inclusion. The next phase may involve pilot studies 
as well as documentation of treatment and laboratory protocols 
before the NSU begins implementing routine screening for the 
recommended condition.
The decision-making framework is currently being used by the 
NSU to evaluate SCID for inclusion in its program. The proposal 
to assess SCID was developed by immunology clinicians before 
being submitted to the NSU (24). The fact that the program is 
reviewing new conditions for screening highlights the capacity 
of evidence-based decision making to enable rational changes to 
newborn screening. The Policy Framework also allows for condi-
tions to be considered for removal from the program. The process 
enables the program to respond to new and emerging evidence, 
and ensure NZ’s families have access to the most appropriate 
newborn screening.
United States
In the US, like Australia, each state is responsible for funding and 
implementing its own newborn screening program. This led to 
inconsistencies in the conditions screened between states, with 
some screening for as few as three conditions and others mandat-
ing as many as 43 (19). In 2002, in response to these inconsisten-
cies, the Health Resources and Services Administration, and the 
American Academy of Pediatrics tasked the American College of 
Medical Genetics (ACMG) with developing a core panel of condi-
tions that should be screened across the US. A total of 84 potential 
conditions were evaluated before a core panel of 25 conditions 
was recommended (19).
To evaluate the 84 conditions for newborn screening, the 
ACMG formed a working group, which included experts in vari-
ous subspecialties of medicine and primary care, health policy, 
law, ethics, and public health as well as consumers. The working 
group used a two-tiered approach for assessing conditions (19). 
The first tier involved conducting a survey to collect informa-
tion on the condition and allow for input from individuals and 
organizations with an interest in screening. The second tier of 
analysis involved establishing a strong evidence base for assessing 
the condition, including gathering scientific knowledge related to 
the test and treatment. From this information, the working group 
determined whether each condition should be recommended as 
either: (a) part of the core panel, (b) a secondary target, or (c) 
excluded from screening.
The recommendations of the ACMG for a core panel of 
conditions were agreed by the Health Resources and Services 
Administration, and subsequently newborn screening was 
expanded. While this process did lead to a national recom-
mendation to screen for a consistent range of conditions, it has 
been criticized by the US Preventative Services Task Force for 
not being in line with accepted standards for evidence-based 
decision making. The Task Force indicated that “the ACMG’s 
approach … relied mostly on colloquial evidence” (25) and that 
there had not been an appropriate level of engagement with the 
community.
In order to provide a more transparent, consistent, and ongo-
ing mechanism to assess conditions for newborn screening, 
the Discretionary Advisory Committee on Heritable Disorders 
in Newborns and Children (the committee) was established in 
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2013 (26). This committee and its operations are funded by the 
Federal Department of Health and Human Services. The process 
used by the committee to assess conditions involves an evidence 
review conducted by an external group. This review summarizes 
evidence from both published and unpublished sources on the 
benefits and harms of screening for the nominated condition 
(27). Using this evidence, the committee assesses both the 
magnitude and the certainty of net benefits from screening (28). 
This includes weighing health benefits to the newborn against the 
harms, and the effectiveness of screening against usual clinical 
care (27).
In addition to analyzing the benefits of screening, the 
committee makes an assessment of states’ readiness to imple-
ment screening for the nominated condition. This includes 
states’ capacity to introduce screening and support both 
short- and long-term follow up of babies diagnosed with 
the condition (27). The committee combines the projected 
net benefits of screening with states’ readiness to screen 
when making a recommendation to include or exclude a 
condition from the recommended panel. Following which, 
recommendations are made to the US Department of Health 
and Human Services. It is then up to each state to decide 
when and how to implement screening for the new condi-
tion within its program. SCID has been added to the panel 
using this revised decision-making process, and a number of 
conditions have been excluded including Pompe disease and 
Krabbe disease (27).
The assessment of conditions for newborn screening in the 
US is conducted and funded at the national level. States are then 
responsible for implementation. However, some national funding 
is available to support program expansion through grants from 
the federal government. These funding arrangements are detailed 
in the Newborn Screening Saves Lives Act, which was passed by the 
US Congress in 2008 and reauthorized in 2014. The purpose of 
this legislation is to support state newborn screening programs to 
expand and improve as well as provide national guidance on what 
conditions should be screened (29).
While the US has a robust decision-making process that 
provides national recommendations to screen, newborn screen-
ing still faces a number of issues at the state level. This comes 
in the form of local pressure from lobbyists, patient groups, or 
well-known personalities, calling for screening for additional 
conditions. An example of this was the introduction of screen-
ing for Krabbe disease in New York state. When the ACMG 
reviewed conditions and developed a national screening panel, 
they specifically excluded Krabbe disease as treatments are still 
experimental. Even so, this condition was added to the newborn 
screening program in New York state after lobbying from a 
prominent former footballer (30). This highlights that even when 
decision-making processes are in place, there are still contextual 
factors, which need to be considered to ensure that the process is 
robust and holds up to local pressure.
United Kingdom
In the UK, the National Health Service, which is responsible 
for providing health services to England, Scotland, Wales, and 
Northern Ireland, established the National Screening Committee 
(NSC) in 1996. This committee provides advice on the devel-
opment, implementation, and review of screening programs, 
including newborn screening (31).
The NSC developed a strict decision-making framework 
for screening, which is broken down into four key steps. The 
first step involves identification of key stakeholders, including 
“patient and professional groups working at a national level” 
(32). Second, an information scientist conducts a systematic 
review of the literature, after which the need for external review 
and consultation is determined. If there is sufficient evidence, 
an external review is undertaken by an expert in the field as 
determined by the NSC. The review is then circulated among key 
stakeholders and the public for their input. Finally, the review is 
considered by the NSC for endorsement. After endorsement, it 
is up to each jurisdiction as to how screening for the condition 
will be implemented.
The NSC decision-making process has been in place since 
2009 and was updated in November 2011 (32). To aid the 
consistency of the process, a comprehensive template for 
nominating conditions, and for conducting external reviews, 
is used. It includes a set of 22 criteria which are assessed as 
met, partially met, not met, or not applicable. Since its imple-
mentation, the template has been used to assess a number 
of conditions for newborn screening including CAH, amino 
and organic acid metabolism disorders, Duchenne muscular 
dystrophy, and SCID. None of these conditions have been 
recommended for screening. However in May 2014, the 
NSC recommended the addition of four new conditions to 
newborn screening (33). This is the first addition of condi-
tions in the UK since 2007, and almost doubles the number 
of conditions screened. This demonstrates that the UK has 
a more conservative approach to assessing conditions than 
many other countries (34).
Other international examples
In addition to the aforementioned processes, a number of other 
countries have recognized the need for a more transparent 
approach to assess conditions for newborn screening. Processes 
exist in the Netherlands (35), Canada (36) and a coordinated 
multi-national approach has been suggested in Europe. In 2009, 
the European Union established the European Union Network of 
Experts on Newborn Screening. This network has completed a 
detailed review of newborn screening in member countries, and 
developed a comprehensive set of recommendations, including 
a proposed model for decision making to assess new conditions 
(37). While this is not a framework per se, it highlights the grow-
ing recognition of the importance of a robust decision-making 
process for newborn screening.
Discussion
Considered decision making by governments for newborn screen-
ing is important to ensure that programs continue to provide 
high quality screening to newborns. Having an agreed, national, 
and structured decision-making process means that conditions 
can be assessed in a transparent and consistent manner. It also 
means that decisions are based on current evidence. This helps to 
TABLe 1 | United States decision-making criteria used to assess aspects 
of the condition for newborn screening (19).
Criteria Categories Score
Incidence of 
condition
>1:5,000
>1:25,000
>1:50,000
>1:75,000
<1:100,000
100
75
50
25
0
Signs and symptoms 
clinically identifiable in 
the first 48 h
Never
<25% cases
<50% cases
<75% cases
Always
100
75
50
25
0
Burden of disease 
(natural history if 
untreated)
Profound
Severe
Moderate
Mild
Minimal
100
75
50
25
0
The US decision-making framework includes 14 criteria against which a condition is 
assessed. The following table is an example of three of the criteria. Conditions are 
scored against the criteria by stakeholders, with data being validated by experts. The 
mean score given for each criterion by stakeholders is then summed. The maximum 
possible score for a condition across all 14 criteria is 2100. Any score above 1200 is 
considered appropriate for inclusion on the recommended core panel for screening.
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avoid technology-driven decisions, which do not systematically 
assess the potential benefits and harms of screening for particular 
conditions.
A recent examination of newborn bloodspot screening across 
the globe highlights that in both developed and developing 
nations, newborn screening programs are either being consid-
ered, or on the verge of some form of expansion (38). As such, 
the current review offers guidance to governments and others to 
ensure that future developments in these countries are evidence-
based and meet the best needs of their populations. Ways in 
which this guidance can be operationalized is explored through 
the Australian setting of a federated health system. Therefore, 
while the following has relevance for all newborn screening set-
tings, it is particularly relevant to those countries where decisions 
about newborn screening are shared between different levels of 
government.
The decision-making processes followed in the UK, US, and 
NZ highlight that, while no one “solution” exists for newborn 
screening, there are common elements between the different 
countries. Namely, the decision-making processes within these 
countries are all:
1. based on the WHO principles, and adapted to suit the local 
environment;
2. triggered by a condition being nominated for assessment 
either by government, health professionals or the public;
3. assessed through multidisciplinary stakeholder engagement, 
to consider the evidence and make recommendations, con-
ducted mostly through committee structures or consultation 
approaches; and
4. developed by government, with decision making and govern-
ance pathways to government.
While the decision-making criteria adhere to the principles 
recommended by Wilson and Jungner, they differ between coun-
tries in the level of detail provided and the way in which evidence 
is considered against them. The US model includes a quantitative 
assessment of the evidence and has resulted in a more liberal 
assessment of conditions (Table 1). Other processes, such as that 
in the UK, can be considered more subjective (Box 3). These dif-
ferences have led to variations in the conditions recommended 
for screening between these countries, with the UK being more 
conservative than the US. It can be argued that other countries 
that are introducing or expanding newborn screening should use 
this knowledge and evidence to find the right balance between 
these two approaches. Striking this balance would support 
robust and transparent assessment of conditions, and facilitate 
evidence-based program development. It would also minimize 
the extent to which lobby groups could influence decision 
making.
In many countries, including the US and the UK, newborn 
screening operates and is managed at a local level. In order to 
promote a national approach to newborn screening, these 
countries employ a national or federal agency to make decisions 
regarding the conditions to be screened. This allows a national 
recommendation to be made by a respected government body 
BOX 3 | United Kingdom decision-making criteria used to assess 
aspects of the condition for newborn screening (32).
The condition:
1. The condition should be an important health problem.
2. Theepidemiology and natural history should be well understood and there 
should be a detectable risk factor, disease marker, latent period or early 
symptomatic stage. 
3. All the cost-effective primary prevention interventions should have been 
implemented asfar as practicable.
4. If carriers of a mutation are identified as a result of screening the natural 
history of people with this disease, this status should be understood, 
including the psychological implications.
and encourages consistency across states. However, neither the 
UK nor the US mandates that recommended conditions are 
adopted by local screening programs. This allows local flexibility 
to implement screening in line with their budgets and timeframes. 
A similar structure could be used in the Australian setting as this 
would allow the state-based programs to maintain autonomy 
while still having conditions assessed through a transparent and 
robust process at the national level.
In Australia, as with other countries, funding is one of the 
biggest barriers to developing and implementing a national 
decision-making framework for newborn screening. This is 
because a decision-making framework has funding implications 
associated with assessing conditions and implementing recom-
mendations. As such, both assessment and implementation 
require financial support from government. Securing increased 
funding, from state, territory, or national governments, to sup-
port decision making or growth of the programs is difficult in 
the current fiscal environment. While this presents a potential 
barrier to progress, there are options for moving forward. There 
are a number of potential funding models, which could be used 
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to support decision making for newborn screening in Australia, 
that are also applicable to other programs.
One option with many benefits is for decision making, and the 
subsequent expansion of a program, to be funded at the national 
level. In Australia, this responsibility would, therefore, fall upon 
the Commonwealth government. Centralized decision making 
and funding would enable a more streamlined transition between 
a recommendation for screening and its subsequent implemen-
tation. However, in Australia funding for newborn screening 
programs has historically come from state and territory govern-
ments, with each state and territory managing its own program. 
For this reason, it is highly unlikely that the Commonwealth 
would support such a model.
In contrast to a nationally funded model, a second option 
would be to have funding for newborn screening decision making 
and implementation divided between state and national govern-
ments. In Australia, this could be achieved through a national 
committee funded via the Australian Health Ministers’ Advisory 
Council funding model. Under this model, the Commonwealth, 
and state and territory governments collectively, each contribute 
50% of funds to a shared budget for health activities. A co-funded 
committee could assess and recommend conditions using a 
national decision-making process. It would then be up to states 
and territories to manage, and fund, the implementation of the 
testing in a manner that suited the local context and budget 
constraints. This model provides a national recommendation, 
while still allowing states to have a level of flexibility to implement 
screening appropriate to their context.
A national decision-making approach, supported by state 
implementation of decisions, would support consistent decision 
making across local-level programs. In Australia, this approach 
also aligns with decision making for other national issues within 
the health system, such as cancer screening. These initiatives 
are supported by federal strategic policy but are implemented 
at the state and territory level. However, even with a national 
decision-making process, there is still the potential for pro-
grams to be influenced by local circumstances. This can occur 
through lobbying or in response to genuine local differences in 
health condition prevalence. This was seen with the inclusion 
of Krabbe disease in the New York state newborn screening 
program.
A third option to support decision making for newborn screen-
ing in countries with regional programs, would be for states to 
fund both the decision-making process and implementation 
of any subsequent recommendations. In Australia, this process 
aligns more closely with the current operations of the program 
and provides states and territories with greater autonomy. It could 
be argued that this process is not all that different from the ways 
in which Australian programs have been expanded in the past: 
decisions are made individually by the states, and implemented 
progressively as their budgets permit. As such, careful steps would 
need to be taken to ensure that this process supports, rather than 
hinders, consistency of the conditions screened and enables 
successful ongoing evolution in response to new technology and 
evidence.
Conclusion
The efforts undertaken internationally to ensure that newborn 
screening is appropriate and effective highlight a significant 
policy gap for Australia. Exploration of these efforts outlines a 
balanced way forward for decision making in Australia. It also 
provides guidance for other countries currently considering 
introducing or expanding newborn screening programs. A 
uniform framework agreed by governments would not only sup-
port consistency into the future, but would provide a transparent 
mechanism to consider the harms and benefits of screening for 
new conditions. This approach would help safeguard the pro-
grams, which are coming under ever growing pressure to screen 
for more conditions. This pressure is arising from the rapid 
growth of new genetic and other diagnostic technologies and 
novel treatments.
At present in Australia, various professional groups are 
working together to fill the decision-making gap that exists for 
newborn screening; however, there is a visible need for a robust 
process, agreed by governments, to support the consideration of 
new conditions. Therefore, the road map for success in Australia 
hinges upon governments coming together to consider the best 
way forward for local programs. To their credit, Australian 
Governments have commenced their journey down this path, and 
are currently drafting a policy framework for newborn bloodspot 
screening. This policy framework will include a decision-making 
framework for assessing conditions. While this is commendable, 
it is only the first step in the process. It is essential that govern-
ments agree this framework and support its implementation in 
order to address the policy gap, and sustain newborn screening 
programs into the future.
Australia has long been an international leader in the field 
of newborn screening. However, indecision by governments at 
the state and national levels, in regards to which conditions to 
screen, has left Australia lacking reliable safeguards to ensure 
the continued success of the programs. In the current situation, 
programs are unable to respond to calls to assess conditions for 
screening or the appropriateness of new technologies. Agreement 
must be reached by governments on a decision-making pathway 
for newborn screening in Australia. Without a national decision-
making process for assessing new conditions, Australian 
newborn screening programs will no longer be able to progress, 
leaving Australia at real risk of falling behind its international 
peers – with consequential implications for the health and well-
being of its citizens.
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